AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Market Cap	171.72B
Revenue (ttm)	16.19B
Net Income (ttm)	969.70M
Shares Out	n/a
EPS (ttm)	38.78
PE Ratio	177.08
Forward PE	n/a
Dividend	24.00 (0.35%)
Ex-Dividend Date	Jul 5, 2024

Volume	6,304
Average Volume	18,708
Open	6,978.70
Previous Close	6,975.80
Day's Range	6,808.15 - 7,022.60
52-Week Range	4,785.00 - 8,139.00
Beta	0.34
RSI	37.78
Earnings Date	Feb 4, 2025

About AstraZeneca Pharma India

AstraZeneca Pharma India Limited, a biopharmaceutical company, engages in manufacturing, distributing, and marketing of pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease, renal, and metabolism medicines under the CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL brand names; oncology medicines under the TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra bran...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1979
• Employees: 940
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ASTRAZEN

Financial Performance

In 2023, AstraZeneca Pharma India's revenue was 12.96 billion, an increase of 29.17% compared to the previous year's 10.03 billion. Earnings were 1.62 billion, an increase of 62.66%.